Patient characteristics (N = 17)
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 14 (82) |
| Female | 3 (18) |
| Mean age, y (SD) | 66.1 (9.2) |
| International Prognostic Index | |
| Low (0-1) | 1 (6) |
| Low-intermediate (2) | 6 (35) |
| High-intermediate (3) | 10 (59) |
| High (4-5) | 0 |
| ECOG performance status | |
| 0 | 8 (47) |
| 1 | 8 (47) |
| 2 | 1 (6) |
| LDH > 1 × ULN | 7 (41) |
| MIPI | |
| Low (< 5.7) | 5 (29) |
| Intermediate (5.7-6.2) | 8 (47) |
| High (> 6.2) | 4 (24) |
| Ki-67 proliferative index | |
| 5%-20% | 0 (0) |
| 21%-40% | 1 (6) |
| 41%-60% | 6 (35) |
| > 60% | 8 (47) |
| Not determined | 2 (12) |
| Combined biologic score (MIPI + Ki67 weight) | |
| Low (< 5.7) | 0 (0) |
| Intermediate (57.6-6.5) | 2 (12) |
| High (> 6.5) | 13 (76) |
| Not determined | 2 (12) |
| Histology at trial entry | |
| Classic | 6 (35) |
| Blastoid | 5 (29) |
| Pleomorphic | 5 (29) |
| Large cell | 1 (6) |
| Prior systemic therapies | |
| 1 | 6 (35.3) |
| 2 | 3 (17.6) |
| 3 | 0 |
| > 3 | 8 (47.1) |
| Prior bortezomib | 9 (53) |
| R-hyper-CVAD | 4 (24) |
| Autologous stem cell transplantation | 3 (18) |
| ≥ 5-cm lesion size | 10 (59) |
| Number of involved disease sites | |
| 1 | 2 (12) |
| 2 | 4 (24) |
| 3 | 6 (36) |
| 4 | 3 (18) |
| > 4 | 2 (12) |
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 14 (82) |
| Female | 3 (18) |
| Mean age, y (SD) | 66.1 (9.2) |
| International Prognostic Index | |
| Low (0-1) | 1 (6) |
| Low-intermediate (2) | 6 (35) |
| High-intermediate (3) | 10 (59) |
| High (4-5) | 0 |
| ECOG performance status | |
| 0 | 8 (47) |
| 1 | 8 (47) |
| 2 | 1 (6) |
| LDH > 1 × ULN | 7 (41) |
| MIPI | |
| Low (< 5.7) | 5 (29) |
| Intermediate (5.7-6.2) | 8 (47) |
| High (> 6.2) | 4 (24) |
| Ki-67 proliferative index | |
| 5%-20% | 0 (0) |
| 21%-40% | 1 (6) |
| 41%-60% | 6 (35) |
| > 60% | 8 (47) |
| Not determined | 2 (12) |
| Combined biologic score (MIPI + Ki67 weight) | |
| Low (< 5.7) | 0 (0) |
| Intermediate (57.6-6.5) | 2 (12) |
| High (> 6.5) | 13 (76) |
| Not determined | 2 (12) |
| Histology at trial entry | |
| Classic | 6 (35) |
| Blastoid | 5 (29) |
| Pleomorphic | 5 (29) |
| Large cell | 1 (6) |
| Prior systemic therapies | |
| 1 | 6 (35.3) |
| 2 | 3 (17.6) |
| 3 | 0 |
| > 3 | 8 (47.1) |
| Prior bortezomib | 9 (53) |
| R-hyper-CVAD | 4 (24) |
| Autologous stem cell transplantation | 3 (18) |
| ≥ 5-cm lesion size | 10 (59) |
| Number of involved disease sites | |
| 1 | 2 (12) |
| 2 | 4 (24) |
| 3 | 6 (36) |
| 4 | 3 (18) |
| > 4 | 2 (12) |
ECOG indicates Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal; and R-hyper-CVAD, rituximab-hyperfractionated cyclophosphamide (Cytoxan), vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone.